ArticleEuropean journal of translational myology2018
Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia.
Article in European journal of translational myology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways.Acta physiologica (Oxford, England) · 2020Pooled it
- Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.Journal of cachexia, sarcopenia and muscle · 2019Trial
- Quercetin attenuates cisplatin-induced muscle atrophy via Hippo/YAP1 signaling pathway.Journal of natural medicines · 2026Article
- Differential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a preclinical model of colorectal cancer by biological sex.American journal of physiology. Endocrinology and metabolism · 2026Article
- Article
- Cancer cachexia: A tumor-driven disorder of whole-body homeostasis.Cancer cell · 2026Review
- The effects of tissue inflammation on cancer cachexia.Biochimica et biophysica acta. Molecular basis of disease · 2026Review
- Prognostic significance and model evaluation of the modified advanced lung cancer inflammation index in locally advanced resectable gastric cancer patients with neoadjuvant chemotherapy.Frontiers in oncology · 2026Article
- Head and neck cancer patients present late cancer cachexia two years after curative chemoradiotherapy.Clinics (Sao Paulo, Brazil) · 2025Article
- Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer.The oncologist · 2025Article
- Medicinal plants: nutritional, immunological and therapeutic role in treating cancer-related malnutrition: a comprehensive review.Cancer cell international · 2025Review
- Cisplatin-Induced Muscle Wasting and Atrophy: Molecular Mechanism and Potential Therapeutic Interventions.Journal of cachexia, sarcopenia and muscle · 2025Review
- Metabolic Implications of Childhood Cancer.Current pediatrics reports · 2025Article
- Diversity in chemotherapy-induced cachexia.American journal of physiology. Cell physiology · 2025Review
- Article
- Sorafenib induces cachexia by impeding transcriptional signaling of the SET1/MLL complex on muscle-specific genes.iScience · 2024Article
- Exploring heterogeneity: a dive into preclinical models of cancer cachexia.American journal of physiology. Cell physiology · 2024Review
- Are measures and related symptoms of cachexia recorded as outcomes in gastrointestinal cancer chemotherapy clinical trials?Journal of cachexia, sarcopenia and muscle · 2024Article
- Article
- Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer.Scientific reports · 2024Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
A compounding feature of greater than 50% of all cancers is the high incidence of the cachexia syndrome, a complex metabolic disorder characterized by extreme weight loss due mainly to the gross depletion of skeletal muscle tissue. Although studies into the cause of cancer cachexia has spanned over multiple decades, little is known about the effects of various cancer treatments themselves on cachexia. For example, chemotherapy agents induce side effects such as nausea and anorexia, but these symptoms do not fully account for the changes seen with cancer cachexia. In this study we examine the effects of chemotherapeutic compounds, specifically, cisplatin in the colon-26 adenocarcinoma model of cancer cachexia. We find that although cisplatin is able to reduce tumor burden as expected, muscle wasting in mice nevertheless persists. Strikingly, cisplatin alone was seen to regulate muscle atrophy, which was independent of the commonly implicated ubiquitin proteasome system. Finally, we show that cisplatin is able to induce NF-κB activity in both mouse muscles and myotube cultures, suggesting that an additional side effect of cancer treatment is the regulation of muscle wasting that may be mediated through activation of the NF-κB signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.